DK1165537T3 - Hydroxymatairesinol til forebyggelse af cancer - Google Patents

Hydroxymatairesinol til forebyggelse af cancer

Info

Publication number
DK1165537T3
DK1165537T3 DK00909388T DK00909388T DK1165537T3 DK 1165537 T3 DK1165537 T3 DK 1165537T3 DK 00909388 T DK00909388 T DK 00909388T DK 00909388 T DK00909388 T DK 00909388T DK 1165537 T3 DK1165537 T3 DK 1165537T3
Authority
DK
Denmark
Prior art keywords
hydroxymatairesinol
person
cancer
prevention
administering
Prior art date
Application number
DK00909388T
Other languages
English (en)
Inventor
Markku Ahotupa
Christer Eckerman
Lauri Kangas
Sari Maekelae
Niina Saarinen
Risto Santti
Anni Waerri
Original Assignee
Hormos Nutraceutical Oy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Nutraceutical Oy Ltd filed Critical Hormos Nutraceutical Oy Ltd
Application granted granted Critical
Publication of DK1165537T3 publication Critical patent/DK1165537T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00909388T 1999-03-30 2000-03-09 Hydroxymatairesinol til forebyggelse af cancer DK1165537T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/281,094 US6451849B1 (en) 1999-03-30 1999-03-30 Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
PCT/FI2000/000181 WO2000059946A1 (en) 1999-03-30 2000-03-09 Hydroxymatairesinol in cancer prevention

Publications (1)

Publication Number Publication Date
DK1165537T3 true DK1165537T3 (da) 2003-05-12

Family

ID=23075932

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00909388T DK1165537T3 (da) 1999-03-30 2000-03-09 Hydroxymatairesinol til forebyggelse af cancer

Country Status (25)

Country Link
US (2) US6451849B1 (da)
EP (1) EP1165537B1 (da)
JP (2) JP4852685B2 (da)
KR (2) KR100741724B1 (da)
CN (1) CN1146553C (da)
AT (1) ATE231500T1 (da)
AU (1) AU767691B2 (da)
BG (1) BG65380B1 (da)
BR (1) BR0007187A (da)
CA (2) CA2650297C (da)
CZ (2) CZ302730B6 (da)
DE (1) DE60001271T2 (da)
DK (1) DK1165537T3 (da)
EE (1) EE200100507A (da)
ES (1) ES2189738T3 (da)
HK (1) HK1045992B (da)
HU (1) HUP0200530A3 (da)
MX (1) MXPA01009714A (da)
NO (4) NO330135B1 (da)
NZ (1) NZ512099A (da)
PL (1) PL199892B1 (da)
RU (1) RU2241453C2 (da)
SK (2) SK287001B6 (da)
WO (1) WO2000059946A1 (da)
ZA (1) ZA200104440B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271257B1 (en) * 2000-04-17 2001-08-07 Hormos Nutraceutical Oy Ltd. Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol
AU2001235969A1 (en) * 2000-10-23 2002-05-06 Council Of Scientific And Industrial Research Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara
WO2003016883A1 (en) * 2001-08-16 2003-02-27 Analiza, Inc. A method of measuring solubility
CA2466663A1 (en) * 2001-11-12 2003-05-22 Analiza, Inc. Characterization of molecules
FI111638B (fi) * 2001-11-23 2003-08-29 Hormos Nutraceutical Oy Ltd Menetelmä hydroksimatairesinolin tuottamiseksi puusta
US7008666B2 (en) * 2001-11-26 2006-03-07 Hormos Nutraceutical Oy Ltd. Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
US20030144216A1 (en) * 2002-01-25 2003-07-31 Mikko Unkila Method for prevention of diseases in coeliac patients
US7528166B2 (en) * 2002-02-05 2009-05-05 Hormos Medical Corporation Lignan derivatives
US7048960B2 (en) * 2002-03-22 2006-05-23 Glenn Roy Pizzey High lignan flaxseed product and product by process
FI20021184A (fi) 2002-06-19 2003-12-20 Hormos Nutraceutical Oy Ltd Lignaanivalmisteita
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
FR2851919A1 (fr) * 2003-03-03 2004-09-10 Lmd Lignanes utilisables comme inhibiteurs de cathepsines et leurs applications
US8099242B2 (en) * 2003-06-12 2012-01-17 Analiza, Inc. Systems and methods for characterization of molecules
FI116727B (sv) 2003-11-12 2006-02-15 Arbonova Ab Oy Ny användning för kvistnötsextrakt
US7976877B2 (en) 2003-11-12 2011-07-12 Oy Arbonova Ab Use of knotwood extracts
KR20060115383A (ko) * 2003-12-26 2006-11-08 노우코우다이 티엘오 가부시키가이샤 간암 예방 및 치료용 조성물
US7666913B2 (en) * 2004-02-03 2010-02-23 Kotosugi Inc. Method of treating or preventing osteoporosis using isotaxiresinol derived from Taxus yunnanensis
AU2005323934A1 (en) * 2005-01-10 2006-07-13 Hormos Medical Ltd The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency
US7595078B2 (en) * 2005-03-15 2009-09-29 Glanbia Nutritionals Ireland Limited Methods of increasing flaxseed hull recovery and resultant flax products
EP1977254B1 (en) 2005-12-19 2012-02-08 Analiza, Inc. Methods involving data patterns such as spectral biomarkers
DE102006008772A1 (de) * 2006-02-22 2007-08-23 Beiersdorf Ag Hydroxymatairesinol gegen trockene Haut
DE102006019044A1 (de) * 2006-04-25 2007-10-31 Merck Patent Gmbh Antioxidantien
FI20106293A0 (fi) * 2010-12-06 2010-12-06 Emilia Peuhu Uudet farmaseuttiset koostumukset
EP2517574B1 (de) 2011-04-29 2015-11-11 Symrise AG Bestimmte Vanillyllignane und deren Verwendung als Geschmacksverbesserer
WO2014025961A1 (en) 2012-08-10 2014-02-13 Analiza, Inc. Methods and devices for analyzing species to determine diseases
RU2510268C1 (ru) * 2012-11-14 2014-03-27 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "Медресурс" Средство для лечения эстрогензависимых опухолей
JP2017515830A (ja) 2014-05-15 2017-06-15 リニア ソシエテ アノニム 7−ヒドロキシマタイレシノールを含む組成物
US9678076B2 (en) 2014-06-24 2017-06-13 Analiza, Inc. Methods and devices for determining a disease state
CZ305794B6 (cs) * 2015-04-20 2016-03-16 Výzkumný ústav potravinářský Praha, v.v.i. Způsob úpravy dřevních suků s přesně regulovanou strukturou drtě pro výrobu lignanů a zařízení k provádění tohoto způsobu, s využitím v potravinářské výrobě
US9669006B2 (en) 2015-07-28 2017-06-06 U.S. Nutraceuticals, LLC Composition and method to treat and alleviate symptoms of hot flashes in a female subject
CN108601803A (zh) * 2015-12-09 2018-09-28 格莱努拉有限公司 组合物用于降低哺乳动物的胆固醇水平的用途,其制备方法,组合物和用于制备包含所述组合物的食品添加剂的方法
IT201700050994A1 (it) * 2017-05-11 2018-11-11 Linnea Sa Uso di una Composizione comprendente 7-Idrossimatairesinolo
AU2022377268A1 (en) 2021-10-28 2024-05-23 Cleveland Diagnostics, Inc Partitioning systems and methods for determining multiple types of cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628228D0 (en) * 1986-11-26 1986-12-31 Inst Biolog Morya Dalnevostoch Composition inhibiting pathological addiction to alcohol
US4808674A (en) * 1987-08-24 1989-02-28 General Electric Company Aryl ester-grafted polyphenylene ethers and phenylene ether-amide graft copolymers prepared therefrom
DE4317466A1 (de) 1993-05-26 1994-12-01 Degussa Verbessertes Verfahren zur Bleiche von Holzstoffen
JPH10511699A (ja) 1995-10-18 1998-11-10 カノルト アルツナイミッテル ゲー エム ベー ハー リグナン及びその製造方法並びに医薬組成物及びその使用方法
WO1997032593A2 (en) 1996-03-08 1997-09-12 Energiser Plc Composition containing iso-flavonoids and lignans
US5846944A (en) 1996-04-04 1998-12-08 The University Of Saskatchewan Purified SDG as an antioxidant
JP2987365B1 (ja) * 1998-10-29 1999-12-06 かどや製油株式会社 抗酸化剤
KR20060115383A (ko) * 2003-12-26 2006-11-08 노우코우다이 티엘오 가부시키가이샤 간암 예방 및 치료용 조성물

Also Published As

Publication number Publication date
NO331188B1 (no) 2011-10-31
NO20014639D0 (no) 2001-09-25
PL350367A1 (en) 2002-12-02
JP4852685B2 (ja) 2012-01-11
CA2371839C (en) 2011-10-04
BG105856A (en) 2002-04-30
NZ512099A (en) 2004-01-30
CZ301725B6 (cs) 2010-06-02
KR20070027770A (ko) 2007-03-09
EE200100507A (et) 2002-12-16
DE60001271D1 (de) 2003-02-27
NO330135B1 (no) 2011-02-21
US6451849B1 (en) 2002-09-17
KR20010108434A (ko) 2001-12-07
BG65380B1 (bg) 2008-05-30
SK13262001A3 (sk) 2002-02-05
JP2002541158A (ja) 2002-12-03
SK287749B6 (sk) 2011-08-04
KR100741724B1 (ko) 2007-07-23
HK1045992B (zh) 2005-02-25
BR0007187A (pt) 2002-02-19
PL199892B1 (pl) 2008-11-28
NO332251B1 (no) 2012-08-06
ATE231500T1 (de) 2003-02-15
CZ302730B6 (cs) 2011-10-05
SK287001B6 (sk) 2009-09-07
AU767691B2 (en) 2003-11-20
US20010016590A1 (en) 2001-08-23
HUP0200530A3 (en) 2002-10-28
CN1146553C (zh) 2004-04-21
EP1165537A1 (en) 2002-01-02
EP1165537B1 (en) 2003-01-22
DE60001271T2 (de) 2003-07-31
CA2650297C (en) 2012-05-15
JP2011052024A (ja) 2011-03-17
NO20014639L (no) 2001-09-25
KR100741723B1 (ko) 2007-07-23
MXPA01009714A (es) 2003-06-24
CA2371839A1 (en) 2000-10-12
HK1045992A1 (en) 2002-12-20
WO2000059946A8 (en) 2001-01-25
NO332110B1 (no) 2012-06-25
NO20101701L (no) 2001-09-25
CZ20013486A3 (cs) 2002-02-13
RU2241453C2 (ru) 2004-12-10
NO20111291L (no) 2001-09-25
WO2000059946A1 (en) 2000-10-12
CA2650297A1 (en) 2000-10-12
AU3169200A (en) 2000-10-23
HUP0200530A2 (hu) 2002-07-29
NO20101067L (no) 2001-09-25
ZA200104440B (en) 2002-07-30
CN1345315A (zh) 2002-04-17
ES2189738T3 (es) 2003-07-16

Similar Documents

Publication Publication Date Title
DK1165537T3 (da) Hydroxymatairesinol til forebyggelse af cancer
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
GB0109146D0 (en) Treatment of type 2 diabetes
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
WO2001036640A3 (en) Human fgf-21 gene and gene expression products
WO2003030934A3 (en) Cpg formulations and related methods
PT977562E (pt) Metodos e composicoes para administracao de taxanos
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
FI963277A (fi) Paramuunisuusinduktori, joka perustuu rokkoviruskomponenttien yhdistelmiin, menetelmä sen valmistamiseksi ja sen käyttö lääkeaineena
WO2001076638A3 (en) Compositions for drug delivery
IL146125A0 (en) Novel quinones as disease therapies
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
WO2004030631A3 (en) Anti-cancer and anti-infectious disease compositions and methods for using same
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
DK1161254T3 (da) Behandling af autoimmune sygdomme med en ekstrakt af amerikansk ginseng
ZA200300675B (en) Pharmaceutical preparation of the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma.
WO2003041645A3 (en) Method of vaccinating a human patient to prevent metastatic tumors
NZ517348A (en) Use of a mycobacterial extract in the treatment of inflammatory bowel disease
IT1277118B1 (it) Composizioni farmaceutiche per il trattamento delle epatopatie croniche
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C